Table 1.
Subjects demonstration
| Characteristics |
OSA n = 99 |
Non-OSA n = 32 |
p- value |
|---|---|---|---|
| Age |
52.2±11.6 |
48.3±13.1 |
0.105 |
| Male, n (%) |
75 (75.8) |
17 (53.1) |
0.025 |
| BMI |
28.9±4.1 |
24.9±4.3 |
0.000 |
|
Epworth Sleepiness Scale |
12.9±4.5 |
12.8±5.5 |
0.884 |
| Total AHI, /h |
53.6±24.7 |
10.1±4.3 |
0.000 |
|
Pulmonary function test |
|
|
|
| FEV1/FVC |
83.7±8.4 |
82±12.5 |
0.394 |
| FEV1 (% predicted) |
82.6±20.1 |
82.6±17.5 |
0.993 |
| FVC (% predicted) |
82.4±17.9 |
86.8±22.3 |
0.278 |
|
Chronic cough |
39 (39.4) |
4 (12.5) |
0.005 |
|
Upper airway cough syndrome |
79 (79.8) |
23 (71.9) |
0.340 |
|
Gastro-esophageal reflux disease |
43 (43.4) |
5 (15.6) |
0.006 |
|
Asthma |
18 (18.2) |
5 (15.6) |
1.000 |
|
Medication |
|
|
|
| Nasal steroid |
72 (72.7) |
20 (62.5) |
0.276 |
| Anti-histamine |
79 (79.8) |
23 (71.9) |
0.340 |
| ACEI or ARB |
11 (11.1) |
0 (0.0) |
0.065 |
| Inhaled corticosteroid |
18 (18.2) |
5 (15.6) |
1.000 |
| Long-acting β2 agonist |
4 (4.0) |
2 (6.2) |
0.634 |
| Proton pump inhibitor | 43 (43.4) | 5 (15.6) | 0.006 |
Data are presented as mean ± SD; BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker.